Do HMG CoA Reductase Inhibitors Affect Abeta Levels?
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
Recent evidence suggests that there is a significant overlap between AD and cerebrovascular
disease. In fact, AD and cerebrovascular disease may share some of the same risk factors,
including hypercholesterolemia. In addition, studies have suggested that the HMG Co-A
reductase inhibitor lipid-lowering agents, known as "statins," decrease the risk of AD by up
to 70%; however, effects differed by specific statin use. This study will compare two
statins, simvastatin (which crosses the blood brain barrier) and pravastatin (which does
not), with respect to their ability to alter blood and cerebrospinal fluid (CSF) levels of AD
and inflammatory markers. The primary aim of the proposed study is to determine whether there
is a reduction in Abeta with statins and whether the ability of the statin to cross the
blood-brain barrier will affect its ability to decrease Abeta. If it can be demonstrated that
statins alter AD-associated biomarkers, this would have broad implications for the treatment
and prevention of AD.
Phase:
Phase 4
Details
Lead Sponsor:
Seattle Institute for Biomedical and Clinical Research